To begin with, I would like to comment on the recent approval T2Biosystems (TTOO) received for a New Technology Add-on Payment ((NTAP)) for its T2Bacteria Panel for FY 2020 as announced by CMS (United States Centers for Medicare & Medicaid Services).
As the CMS said:
The T2Bacteria Test Panel represents a substantial clinical improvement over existing technologies because it reduces the proportion of patients on inappropriate therapy, thus reducing the rate of subsequent diagnostic or therapeutic intervention as well as length of stay and mortality rates caused by sepsis causing bacterial infections.
Please